US Broker Ratings

Xenon Pharmaceuticals Inc. (XENE) Stock Analysis: Uncovering a 75% Upside Potential in Biotech

Xenon Pharmaceuticals Inc. (NASDAQ: XENE) is a Canadian biotechnology company at the forefront of developing innovative treatments for neurological and psychiatric disorders. With a market capitalization..

LivaNova PLC (LIVN): Investor Outlook on a Medical Device Giant with 44% Upside Potential

LivaNova PLC (NASDAQ: LIVN), a formidable player in the healthcare sector, focuses on medical devices, specifically for neurological and cardiac conditions. Headquartered in London, the company..

Metsera, Inc. (MTSR) Stock Analysis: Promising 37.81% Upside in the Biotech Sector

Metsera, Inc. (NASDAQ: MTSR), a clinical-stage biotechnology company based in New York, is quickly capturing investor attention with its innovative approach to treating obesity and related..

SpringWorks Therapeutics, Inc. (SWTX) Stock Analysis: Navigating Growth in Rare Diseases and Cancer Treatment

SpringWorks Therapeutics, Inc. (SWTX) is a commercial-stage biopharmaceutical company making waves in the healthcare sector, particularly in the niche markets of rare diseases and cancer treatments...

DENTSPLY SIRONA Inc. (XRAY) Stock Analysis: Exploring a 16% Potential Upside in the Healthcare Sector

DENTSPLY SIRONA Inc. (NASDAQ: XRAY), a prominent player in the healthcare sector known for its innovative dental solutions, presents a compelling opportunity for investors seeking exposure..

Alignment Healthcare, Inc. (ALHC) Stock Analysis: Unpacking 45.78% Potential Upside in the Healthcare Sector

For investors with a keen eye on the healthcare sector, Alignment Healthcare, Inc. (ALHC) presents a compelling opportunity. The company, which provides Medicare Advantage plans tailored..

ACADIA Pharmaceuticals Inc. (ACAD) Investor Outlook: A Potential 28.98% Upside as CNS Drug Portfolio Expands

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is making waves in the biopharmaceutical sector, particularly with its promising treatments targeting central nervous system (CNS) disorders and rare diseases...

CRISPR Therapeutics AG (CRSP) Stock Analysis: Evaluating the 25.14% Potential Upside Amidst Revolutionary Gene-Editing Innovations

CRISPR Therapeutics AG (NASDAQ: CRSP), a leading name in the biotechnology industry, is capturing investor attention with its promising gene-editing platform and the potential for substantial..

Sotera Health Company (SHC) Stock Analysis: A 35% Upside Potential Awaits Investors

Sotera Health Company (SHC), a prominent player in the healthcare industry’s diagnostics and research sector, offers an intriguing investment opportunity, particularly for those eyeing substantial growth..

TransMedics Group, Inc. (TMDX) Stock Analysis: Exploring the 23.64% Potential Upside in the Healthcare Sector

TransMedics Group, Inc. (NASDAQ: TMDX) stands as an intriguing player in the healthcare sector, particularly within the medical devices industry. Having carved out a niche in..

Avidity Biosciences, Inc. (RNA) Investor Outlook: Exploring a 99% Potential Upside in the Biotech Sector

Avidity Biosciences, Inc. (NASDAQ: RNA) is carving a niche within the biotechnology sector by focusing on RNA therapeutics, specifically through its innovative Antibody Oligonucleotide Conjugates (AOCs)...

Krystal Biotech (KRYS): Biotech Innovator with 39% Upside Potential

Krystal Biotech, Inc. (NASDAQ: KRYS), a trailblazer in the biotechnology sector, is capturing the attention of investors with its promising genetic medicine portfolio. With a current..

Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Exploring a Potential 241% Upside in a Volatile Biotechnology Sector

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stands as a significant player in the biotechnology industry, a sector known for its rapid innovation and high-risk, high-reward investment opportunities...

Prestige Consumer Healthcare Inc. (PBH) Stock Analysis: Evaluating a 16.8% Potential Upside for Investors

Prestige Consumer Healthcare Inc. (NYSE: PBH), a prominent player in the healthcare sector, offers investors a compelling opportunity with a potential upside of 16.8%, according to..

Akero Therapeutics (AKRO) Stock Analysis: A 46.51% Upside Potential in the Biotechnology Space

For investors with an eye on the biotechnology sector, Akero Therapeutics, Inc. (NASDAQ: AKRO) presents a compelling opportunity, boasting a potential upside of 46.51% according to..

Madrigal Pharmaceuticals (MDGL) Stock Analysis: Potential 26.64% Upside in Biotech Innovation

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is gaining the attention of investors with its promising pipeline in the biotechnology sector, particularly focusing on metabolic dysfunction-associated steatohepatitis (MASH)...

Legend Biotech Corporation (LEGN): Explosive Growth Potential with 83.74% Upside

Legend Biotech Corporation (NASDAQ: LEGN) is capturing the attention of the biotechnology sector with its innovative approach to cancer treatment and a robust pipeline of novel..

Corcept Therapeutics (CORT): Investor Outlook with Nearly 95% Upside Potential

For investors with a keen eye on the biotechnology sector, Corcept Therapeutics Incorporated (NASDAQ: CORT) presents an intriguing opportunity. With a robust market capitalization of $7.51..

Charles River Laboratories (CRL) Investor Outlook: Navigating Challenges with Strategic Opportunities

Charles River Laboratories International, Inc. (NYSE: CRL) is a significant player in the healthcare sector, primarily focused on diagnostics and research. With a market capitalization of..

Telix Pharmaceuticals Limited (TLX): Analyst Ratings Signal 40% Potential Upside in Biotech Innovator

Telix Pharmaceuticals Limited (TLX), a burgeoning player in the healthcare sector, specifically within the biotechnology industry, is capturing investor attention with its promising growth potential and..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds